Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor

Abstract

Abstract: Nuclear-cytoplasmic translocation is an important cause of abnormal gene localization, which occurs at various stages of tumor development and is closely related to tumor treatment and drug resistance. In this paper, the basic structure, biological function and regulatory mechanism of nuclear translocation are described, and the role of nuclear-cytoplasmic translocation in the genesis and development of tumors, as well as the progress in tumor therapy and drug resistance are further reviewed, in order to provide theoretical basis for exploring novel anti-tumor strategies.

Key words: nuclear-cytoplasmic translocation, molecular mechanism, therapy, research progress

CLC Number:

R730.23

ZHOU Jie, HUANG Ying-hui. Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor[J]. Basic & Clinical Medicine, 2020, 40(8): 1119-1123.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68:7-30.
[2] Li FL, Liu JP, Bao RX, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis[J]. Nat Commun, 2018,9:508. doi:10.1038/s41467-018-02950-5.
[3] Lin DH, Correia AR, Cai SW, et al. Structural and functional analysis of mRNA export regulation by the nuclear pore complex[J]. Nat Commun, 2018,9:2319. doi:10.1038/s41467-018-04459-3.
[4 ] Bui KH, von Appen A, DiGuilio AL, et al. Integrated structural analysis of the human nuclear pore complex scaffold[J]. Cell, 2013,155:1233-1243.
[5] Zhou M, Liu H, Xu X, et al. Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression[J]. J Cell Biochem, 2006,98:920-930.
[6] Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes[J]. Mol Biol Cell, 2012,23:3673-3676.
[7] Tavolieri MV, Droppelmann CA, Campos-Melo D,et al. A novel overlapping NLS/NES region within the PH domain of Rho guanine nucleotide exchange factor(RGNEF) regulates its nuclear-cytoplasmic localization[J]. Eur J Cell Biol, 2019, 98: 27-35.
[8] Chook YM, Blobel G. Karyopherins and nuclear import[J]. Curr Opin Struct Biol, 2001,11:703-715.
[9] Kapinos LE, Huang B, Rencurel C, et al. Karyopherins regulate nuclear pore complex barrier and transport function[J]. J Cell Biol, 2017,216:3609-3624.
[10] Barbato S, Kapinos LE, Rencurel C, et al. Karyopherin enrichment at the nuclear pore complex attenuates Ran permeability[J]. J Cell Sci, 2020,133.doi:10.1242/jcs.238121.
[11] Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention[J]. Nat Rev Cancer, 2004,4:106-117.
[12] Plafker K, Macara IG. Facilitated nucleocytoplasmic shuttling of the Ran binding protein RanBP1[J]. Mol Cell Biol, 2000,20:3510-3521.
[13] Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2018,18:335-345.
[14] Rahmani K, Dean DA. Leptomycin B alters the subcel-lular distribution of CRM1 (Exportin 1)[J]. Biochem Biophys Res Commun, 2017,488:253-258.
[15] Stelma T, Leaner VD. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells[J]. Oncotarget, 2017,8:32833-32847.
[16] Cooper JP, Reynolds CP, Cho H, et al. Clinical development of fenretinide as an antineoplastic drug: pharm-acology perspectives[J]. Exp Biol Med (Maywood), 2017,242:1178-1184.
[17] Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway[J]. Nat Cell Biol, 2014,16:357-366.
[18] Cyert MS. Regulation of nuclear localization during Signaling[J]. J Biol Chem, 276:20805-20808.
[19] de Polo A, Luo Z, Gerarduzzi C, et al. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex[J]. J Mol Cell Biol, 2017,9:154-165.
[20] Liu H, Zhang H, Wu X, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis[J]. Nature, 2018,563:131-136.
[21] Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in kras-mutant lung cancer[J]. Nature, 2016,538:114-117.
[22] Wang J, Lu Q, Cai J, et al. Nestin regulates cellular redox homeostasis in lung cancer through the keap1-nrf2 feedback loop[J]. Nat Commun, 2019,10:5043. doi:10.1038/s41467-019-12925-9.
[23] Lee PC, Fang YF, Yamaguchi H, et al. Targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer[J]. Cancer Cell, 2018,34:954-969.

[1]	WANG Liang, XIA Longkuo, ZHANG Jianmin. Research progress of brain organoids in drug development [J]. Basic & Clinical Medicine, 2024, 44(9): 1208-1213.
[2]	HAN Yingdong, WANG Song, ZHANG Yun, ZENG Xuejun. Analysis of clinical features of hypereosinophilic syndrome complicated with peripheral arterial embolism [J]. Basic & Clinical Medicine, 2024, 44(8): 1157-1161.
[3]	GAO Yidan, JIANG Xuehan, ZHANG Hong, YANG Peiran. Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension [J]. Basic & Clinical Medicine, 2024, 44(8): 1088-1093.
[4]	ZHANG Wei, ZHANG Zhen, LIU Dong, JIANG Houzhou, LIANG Wei. Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma [J]. Basic & Clinical Medicine, 2024, 44(7): 1018-1022.
[5]	LIU Jinghua, LU Lin. Genetic and molecular mechanism changes of adrenocortical carcinoma [J]. Basic & Clinical Medicine, 2024, 44(6): 748-752.
[6]	DUAN Ran, LI Qingyuan, FENG Tong. Metabolic reprogramming in idiopathic pulmonary fibrosis [J]. Basic & Clinical Medicine, 2024, 44(6): 882-886.
[7]	Growth and Development and Gonadal Diseases Committee of Chinese Aging Well Association. Consensus on endocrine management for children and adolescents with craniopharyngioma surgeries [J]. Basic & Clinical Medicine, 2024, 44(5): 585-598.
[8]	FU Chen, LI Ping. Research progress in the treatment of severe aplastic anemia [J]. Basic & Clinical Medicine, 2024, 44(5): 719-723.
[9]	LIU Zhen, WANG Dalian, ZHANG Jie, ZHANG Qixing, WANG Fei. Intensive phototherapy don't affect cellular immune function and short-term reactions after discharge in neonatal hyperbilirubinemia [J]. Basic & Clinical Medicine, 2024, 44(3): 379-383.
[10]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[11]	. Drug therapy for intracranial germ cell tumor [J]. Basic & Clinical Medicine, 2024, 44(10): 1350-1356.
[12]	. Advances in pharmacotherapy for angiosarcoma [J]. Basic & Clinical Medicine, 2024, 44(10): 1363-1367.
[13]	. Targeted therapy and immunotherapy for malignant mesothelioma [J]. Basic & Clinical Medicine, 2024, 44(10): 1342-1349.
[14]	. Role of Ghrelin in gastric cancer [J]. Basic & Clinical Medicine, 2024, 44(10): 1460-1464.
[15]	. Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC [J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.